CJC-1295 DAC Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What CJC-1295 DAC Does & How It Works

What It Does - Functional Outcomes

• Stimulates the pituitary gland to release growth hormone in a sustained, pulsatile pattern from a single weekly injection
• Drives IGF-1 production from the liver via the GH/IGF-1 axis, with IGF-1 elevation persisting up to 28 days with repeated dosing
• Supports protein synthesis signaling and lean tissue preservation through downstream IGF-1 receptor activation
• Modulates fat metabolism via GH's lipolytic effects on adipose tissue
• Promotes cellular growth and repair signaling through PI3K/Akt and MAPK/ERK pathway activation
• Does not meaningfully raise cortisol, prolactin, or ACTH at the dose ranges studied in humans

How It Works - Mechanism of Action

GHRH Receptor Agonism and cAMP-Mediated GH Secretion (Evidence: Human)

CJC-1295 DAC binds selectively to the growth hormone-releasing hormone receptor (GHRHR) - a G-protein-coupled receptor located on somatotroph cells in the anterior pituitary. Binding activates adenylyl cyclase through Gs protein coupling, which raises intracellular cyclic AMP levels. Elevated cAMP activates protein kinase A, which drives GH gene transcription and growth hormone synthesis, producing dose-dependent GH secretion measured at 2- to 10-fold above baseline in human subjects at optimal doses.

Albumin Covalent Binding - The DAC Technology (Evidence: Human)

The N-epsilon-maleimidopropionamide modification on the C-terminal lysine of CJC-1295 DAC undergoes a selective chemical reaction with cysteine-34 of serum albumin - the only free thiol group on the albumin molecule. This forms a stable, covalent peptide-albumin bioconjugate that circulates in the bloodstream. The resulting complex carries a measured half-life of 5.8-8.1 days in humans, representing a greater than 1,000-fold extension over native GHRH's half-life of approximately 7 minutes.

Pulsatility Preservation Under Continuous Stimulation (Evidence: Human)

Despite the extended half-life creating a state of sustained GHRH receptor stimulation, the pituitary maintains its natural pulsatile GH release pattern. This is mechanistically distinct from continuous exogenous GH infusion, which suppresses pulsatility. Somatostatin inhibition and other hypothalamic-pituitary feedback mechanisms remain active during CJC-1295 DAC exposure, preventing the complete receptor desensitization that sustained stimulation might otherwise produce.

IGF-1 Production via GH/Hepatic Signaling (Evidence: Human)

Released GH circulates to the liver and binds hepatic GH receptors, activating the JAK-STAT signaling pathway - specifically JAK2 and STAT5 - which induces IGF-1 synthesis and secretion. Circulating IGF-1 then activates PI3K/Akt signaling (cell survival, protein synthesis, glucose metabolism) and MAPK/ERK signaling (cell proliferation, growth) across peripheral tissues. IGF-1 elevation following a single injection persists for 9-11 days; with repeated dosing, it can remain above baseline for the full 28-day period.

DPP-IV Resistance from Structural Modifications (Evidence: Mechanistic)

The D-alanine substitution at position 2 of the peptide sequence is the primary defense against dipeptidyl peptidase IV (DPP-IV) - the enzyme that rapidly degrades native GHRH in plasma. D-amino acids are stereochemically distinct from the L-amino acids that mammalian proteolytic enzymes are designed to process. Three additional amino acid substitutions at positions 8, 15, and 27 provide further resistance to proteolytic cleavage, giving CJC-1295 DAC multilayered structural stability even before albumin-binding adds another layer of physical protection.

CJC-1295 DAC Molecular Profile

Structure reference: View CJC-1295 DAC on PubChem (CID 56841945)

CJC-1295 DAC Uses & Benefits

Growth Hormone Support and the GH/IGF-1 Axis

CJC-1295 DAC is primarily used in research contexts aimed at elevating growth hormone and IGF-1 in a sustained, physiologically patterned way. The compound targets the GHRH receptor on pituitary somatotrophs - the same receptor that the body's own GHRH activates - making it a signal amplifier rather than a hormone replacement. The human Phase I data confirms dose-dependent GH elevation of 2- to 10-fold and IGF-1 elevation of 1.5- to 3-fold from a single weekly injection, with sustained levels across the dosing interval. (Evidence: Strong - human Phase I)

Body Composition and Lean Tissue Support

The downstream effects of elevated GH and IGF-1 include enhanced protein synthesis signaling, support for lean tissue preservation, and modulation of fat metabolism through GH's lipolytic effects on adipose tissue. These mechanisms are established in the broader GH/IGF-1 biology literature, and they are why CJC-1295 DAC is commonly included in body composition protocols by practitioners and researchers working with adult populations experiencing age-related GH decline. Dedicated clinical trial data for body composition outcomes specific to CJC-1295 DAC does not yet exist. (Evidence: Preliminary - mechanistically grounded via established GH/IGF-1 biology)

Recovery and Tissue Repair

IGF-1's activation of PI3K/Akt and MAPK/ERK pathways supports cellular repair, protein synthesis, and tissue regeneration signaling. Recovery-oriented protocols frequently pair CJC-1295 DAC with other compounds to combine sustained IGF-1 elevation with more targeted repair mechanisms. The sustained IGF-1 elevation characteristic of CJC-1295 DAC - up to 28 days with repeated dosing - is considered advantageous in recovery contexts where maintaining elevated anabolic signaling across the recovery period is the goal. No dedicated clinical trial data examines CJC-1295 DAC for injury recovery specifically. (Evidence: Preliminary - mechanistically grounded; community and practitioner documentation)

Longevity and Age-Related GH Decline (Somatopause)

GH secretion declines steadily with age - a phenomenon sometimes called somatopause - and the downstream effects on IGF-1, body composition, bone density, and cellular repair are well documented in the aging biology literature. CJC-1295 DAC is studied and used in longevity contexts as a means of restoring more youthful GH pulsatility patterns in older adults. The Phase I human trials enrolled adults up to age 61, providing some data points in the older adult range, though no dedicated study of CJC-1295 DAC in somatopause populations has been published. (Evidence: Preliminary - somatopause biology is established; compound-specific longevity data is not)

Sleep Quality

GH secretion has a well-established relationship with slow-wave sleep - the deepest stage of the sleep cycle. The body's largest natural GH pulse occurs during the first slow-wave sleep cycle of the night. Elevated GH secretion from CJC-1295 DAC is frequently reported by users to improve sleep depth and quality, and this is one of the earlier-reported subjective effects in community protocol data. No controlled sleep study has been conducted for CJC-1295 DAC specifically, and the mechanism is inferred from the broader GH-sleep relationship. (Evidence: Preliminary - mechanism inferred; community-reported)

Where This Guide Comes From

CJC-1295 DAC Results & Timelines

GH and IGF-1 Elevation

• Hours 1-24: GH elevation is measurable on the day of injection in the Phase I trial data; subjective effects are rarely noticed this early
• Week 1-2: The first subjective changes most commonly reported are improved sleep depth and quality - typically the earliest-noticed outcome in real-world protocol logs; some users report increased energy in this window
• Week 3-4: Recovery perception and workout output changes begin appearing in tracked protocols; IGF-1 accumulation from repeated weekly dosing is building toward a sustained elevated baseline
• Week 6-8: Body composition changes - including lean tissue support and fat metabolism effects - become noticeable in many documented protocols at this stage; consistent dosing over this period is associated with more pronounced outcomes

Body Composition and Recovery

• Week 1-3: Minimal observable body composition change; the anabolic signaling is active but structural changes require more time to accumulate
• Week 4-6: Early recovery improvements and training adaptation support typically reported; some users note reduced muscle soreness and faster return-to-baseline after training
• Week 8-12: Cumulative lean tissue support effects become more apparent in protocols where training and nutrition are consistent; the majority of documented body composition outcomes are reported in this window
• Beyond 12 weeks: Fewer data points available from published sources given the 49-day maximum human trial period; community protocol logs vary widely in this range

Cognitive and Wellbeing Effects

• Week 1-4: Some users in community protocol documentation report subjective mood and cognitive clarity improvements in the first month; these are not captured in the Phase I trial data and should be considered anecdotal
• Week 4+: Wellbeing and energy effects, where reported, tend to persist throughout the active protocol period

How to Administer CJC-1295 DAC

Subcutaneous Injection (SubQ)

Subcutaneous injection is the only administration route used in all published human clinical trials for CJC-1295 DAC. SubQ delivery deposits the peptide into the fatty tissue just beneath the skin, where it enters the systemic circulation and forms the albumin bond that drives the compound's extended pharmacokinetics. Common SubQ injection sites include the abdomen, outer thigh, and upper arm. The SubQ route is preferred for GHRH analogs because of its consistent absorption and the absence of any demonstrated advantage for deeper injection with this class of compound.

Intramuscular Injection (IM)

No published clinical or preclinical data specifically examines intramuscular administration of CJC-1295 DAC. IM injection is not the established route for this compound. Given that pharmacokinetics are governed by albumin binding rather than injection depth, there is no documented pharmacological rationale for preferring IM over SubQ for CJC-1295 DAC. Community use of SubQ is overwhelmingly dominant.

Oral

Oral administration of CJC-1295 DAC is not viable. As a 30-amino-acid peptide with a molecular weight of approximately 3,648 g/mol, it would be broken down by gastric acid and digestive proteases in the gastrointestinal tract long before reaching systemic circulation. The albumin-binding reaction that defines the compound's mechanism requires the intact peptide to reach the bloodstream - something oral delivery cannot achieve with a molecule of this size and complexity.

CJC-1295 DAC Dosage & Cycle Length

Overall dosing range: Phase I human clinical trials identified an optimal tolerability window for subcutaneous injection, administered once weekly given the 5.8-8.1 day half-life. The lower end of the studied range was associated with the best tolerability profile, while the upper end of the optimal range produced stronger GH and IGF-1 responses while remaining within the documented tolerability window.

How the goal shifts where you land:

• Lower end of the studied range: associated with the best tolerability profile in clinical trial data; appropriate starting reference point for research protocols prioritizing safety margin
• Upper end of the optimal range: produces stronger GH and IGF-1 responses while remaining within the documented tolerability window
• Above the optimal range: tested in Phase I trials but associated with notably higher adverse event rates; not within the identified optimal window

Frequency: Given the 5.8-8.1 day half-life, once-weekly injection is the minimum scientifically rational interval. Community and practitioner protocols most commonly document once-weekly to once every two weeks dosing, reflecting the compound's unusually long active window relative to other GHRH analogs.

Cycle length: Human trial observation periods covered 28-49 days. Longer-term safety data beyond this window is not available from the published literature. Community and practitioner protocols vary - some document shorter focused cycles of 8-12 weeks, others use longer runs with periodic breaks. Given the theoretical concern about GHRH receptor downregulation with prolonged continuous stimulation, many practitioners favor cycling approaches over indefinite continuous use.

Loading protocols: No formal loading protocol has been established or studied in published literature. The compound's pharmacokinetics do not suggest a biological rationale for front-loading given that steady-state GH and IGF-1 elevation is achieved rapidly from the first injection.

CJC-1295 DAC Vial Sizes, Costs & Quality

Common vial sizes: 2 mg and 5 mg are the most widely available sizes for CJC-1295 DAC in the current research peptide market; 10 mg vials are available from some suppliers

Typical cost range: $45-$90 per vial for U.S.-manufactured research-grade CJC-1295 DAC at current market pricing - varies by vial size, supplier, and purity level; 5 mg vials typically fall in the $60-$90 range from domestic manufacturers

Storage - lyophilized (dry powder):

• Temperature: Store at -20 degrees C for long-term storage; stable for approximately 24 months when stored properly
• Shelf life: Approximately 24 months lyophilized at recommended temperature
• Light sensitivity: Protect from light; store in original sealed vial away from direct sunlight

Storage - reconstituted (in solution):

• Temperature: Refrigerate at 2-8 degrees C after reconstitution
• Use window: Typically 14-21 days once reconstituted; use within this window to maintain peptide integrity

Normal appearance after reconstitution: CJC-1295 DAC typically dissolves into a clear, colorless to very slightly off-white solution. Complete dissolution should occur with gentle agitation - do not shake the vial vigorously. The solution should be free of visible particulates.

Signs of degradation: Cloudiness beyond the expected clear appearance, visible clumping or floating particulates, discoloration to yellow or brown, or an unusual odor are indicators of degradation. Degraded peptide should not be used.

Quality Considerations

Peptide purity is not visible to the naked eye, and that is exactly the problem with sourcing CJC-1295 DAC from unverified suppliers. A vial can look perfectly clear and still contain a compound that is underdosed, incorrectly synthesized, or contaminated with residual solvents or endotoxins from cheap overseas manufacturing processes. The amino acid substitutions and the DAC modification in CJC-1295 DAC require precise synthetic chemistry - when synthesis is rushed or quality controls are skipped, the modifications can be wrong or absent, meaning the compound may have none of the extended half-life it is supposed to deliver. U.S.-manufactured research peptides come with third-party certificate of analysis documentation, verified purity by HPLC testing, and traceability from synthesis to shipment - the kind of accountability that overseas bulk suppliers do not provide. When you are dealing with a compound whose mechanism depends on precise structural modifications, the quality of synthesis is not a secondary concern.

CJC-1295 DAC Side Effects & Safety

Side Effect Spectrum

Contraindications

• Active malignancy: GH and IGF-1 elevation may theoretically support tumor growth via IGF-1 receptor signaling; use is not appropriate in the presence of active cancer
• Acromegaly or conditions of GH excess: CJC-1295 DAC further elevates GH and IGF-1; use in individuals with pre-existing GH excess or acromegaly is not appropriate
• Insulin resistance or uncontrolled diabetes: GH is counter-regulatory to insulin and may worsen glucose management; insufficient data to confirm safety in this population without medical monitoring

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: Insufficient safety data; use is not recommended without medical supervision
• Pediatric use: Not studied in pediatric populations; not appropriate without medical supervision
• Individuals with elevated baseline IGF-1: Those with already elevated IGF-1 levels should be aware that CJC-1295 DAC may push levels higher, with potential downstream effects on glucose regulation and cell proliferation signaling
• Individuals taking insulin or diabetes medications: GH's counter-regulatory effect on insulin means blood glucose dynamics may be affected; co-administration warrants medical monitoring

Red Flags - Stop Use and Seek Medical Attention If:

• Severe or persistent injection site reaction extending beyond local redness and swelling
• Severe or prolonged dizziness, loss of coordination, or neurological symptoms not resolving within 24 hours
• Significant edema or unexplained rapid weight gain
• New or worsening joint pain or carpal tunnel-type symptoms with continued use
• Any unusual symptoms suggesting cardiovascular involvement, including chest discomfort or marked blood pressure changes

Drug and Compound Interactions

No formal drug interaction studies for CJC-1295 DAC have been published in the available literature. Theoretical interactions exist with insulin and hypoglycemic agents - GH's counter-regulatory effects on insulin mean that co-administration may alter glucose dynamics and insulin requirements. Simultaneous use with other GH secretagogues (including GHRPs such as ipamorelin or GHRP-6) may amplify GH release beyond what either compound produces alone; while this is intentional in some stacking protocols, it also increases the potential for side effects associated with GH excess. Interactions with sex hormone therapies have not been formally studied but are theoretically relevant given GH's relationship with sex hormones in anabolic signaling.

CJC-1295 DAC Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability

CJC-1295 DAC is administered subcutaneously in all published human studies. After injection, the DAC maleimide group rapidly undergoes a selective covalent reaction with cysteine-34 of circulating serum albumin, forming a stable peptide-albumin bioconjugate. This reaction is the pharmacokinetic foundation of the compound - once bound to albumin, the peptide adopts albumin's kinetic profile. Bioavailability is established through the Phase I pharmacokinetic work by Teichman et al. (2006), which confirmed measurable and sustained plasma GH elevation beginning within hours of injection and persisting for at least six days.

Distribution

Because the compound circulates as an albumin bioconjugate, its distribution follows albumin's kinetics rather than those of a free small molecule. Albumin is largely confined to the vascular compartment and interstitial fluid, meaning CJC-1295 DAC does not penetrate cells or cross the blood-brain barrier to any meaningful degree. Its site of pharmacodynamic action - the GHRH receptor on anterior pituitary somatotrophs - is accessible from the systemic circulation without requiring CNS penetration.

Half-Life

The plasma half-life in humans is 5.8-8.1 days, as directly measured in the Teichman et al. (2006) Phase I trials. This represents a greater than 1,000-fold extension over native GHRH's half-life of approximately 7 minutes in human plasma. The half-life is governed primarily by albumin turnover kinetics, since the peptide is covalently bound to the carrier protein.

Metabolism & Elimination

Specific metabolic and excretion pathways for CJC-1295 DAC remain incompletely characterized in the published literature. Elimination is likely governed by albumin catabolism, which proceeds primarily through lysosomal degradation in endothelial cells and the reticuloendothelial system, with constituent amino acids entering normal recycling pathways. No evidence of drug accumulation was observed across multiple-dose protocols in the Phase I trials.

A notable pharmacodynamic feature worth flagging: the biological effects of CJC-1295 DAC - particularly sustained IGF-1 elevation - persist beyond the period when intact peptide is detectable in plasma. IGF-1 remained elevated for up to 28 days in the multiple-dose protocol arms of the Phase I trials, suggesting that downstream hormonal effects significantly outlast the drug's own measurable presence. This pharmacodynamic-pharmacokinetic disconnect is described as a unique characteristic of the albumin-bioconjugate approach.

Mechanistic Research

GHRH Receptor Agonism and cAMP-Mediated GH Secretion (Evidence: Human - Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism)

CJC-1295 DAC binds selectively to the GHRH receptor on anterior pituitary somatotroph cells, activating Gs protein-coupled adenylyl cyclase and increasing intracellular cyclic AMP. Elevated cAMP activates protein kinase A, which drives GH gene transcription (GH1 gene) and GH synthesis. This cascade produces dose-dependent GH secretion measured at 2- to 10-fold above baseline in human subjects at the optimal dose range. The albumin-bound form of the compound delivers this stimulation continuously across the dosing interval, which is what separates the pharmacodynamic profile of CJC-1295 DAC from shorter-acting GHRH analogs.

Albumin Covalent Binding and Half-Life Extension (Evidence: Human - Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism)

The N-epsilon-maleimidopropionamide modification on the C-terminal lysine undergoes a selective thioether reaction specifically targeting cysteine-34 of serum albumin - the only free thiol group on the albumin molecule. This forms a stable, covalent peptide-albumin bioconjugate with a measured half-life of 5.8-8.1 days. The selectivity of the reaction for cysteine-34 on albumin was a deliberate design feature of the DAC technology, and no significant nonspecific protein interactions were reported in the published literature.

Pulsatile GH Secretion Under Continuous Stimulation (Evidence: Human - Ionescu & Frohman, 2006, Journal of Clinical Endocrinology & Metabolism)

Despite the extended half-life creating a state of continuous GHRH receptor stimulation, Ionescu and Frohman demonstrated using frequent GH sampling that the pituitary maintains its natural pulsatile GH release pattern. This is mechanistically distinct from continuous exogenous GH infusion, which suppresses pulsatility. The finding implies that somatotroph feedback mechanisms - including somatostatin inhibition - remain functional during CJC-1295 DAC exposure, preventing the complete desensitization that continuous receptor activation might otherwise produce.

Somatotroph Effects and GH Gene Expression in Deficiency Models (Evidence: Animal - preclinical)

In GHRH knockout mice - an animal model of GH deficiency - chronic CJC-1295 DAC administration normalized pituitary gland structure, increased total pituitary RNA, increased GH mRNA expression, and produced apparent increases in somatotroph cell number. These findings suggest the compound may support somatotroph restoration and enhanced GH production capacity in deficiency states, beyond simply stimulating acute GH release. Daily dosing produced more pronounced effects than intermittent dosing in this model, demonstrating dose-frequency dependency.

DPP-IV Resistance from Structural Modifications (Evidence: Mechanistic / structural chemistry)

The D-alanine substitution at position 2 is the primary mechanism of resistance against dipeptidyl peptidase IV (DPP-IV) - the enzyme responsible for the rapid degradation of native GHRH. D-amino acids are stereochemically distinct from L-amino acids and are not efficiently processed by most mammalian proteolytic enzymes. Combined with three additional amino acid substitutions at positions 8, 15, and 27, CJC-1295 DAC has substantially reduced susceptibility to proteolytic cleavage even before albumin-binding adds another layer of physical protection.

Condition-Focused Research

Growth Hormone Physiology and the GH/IGF-1 Axis {#research-gh-axis}

The primary Phase I trials by Teichman et al. (2006) enrolled 66 healthy adults aged 21-61 years across two randomized, double-blind, placebo-controlled studies. Participants received single subcutaneous injections across multiple dose levels, with pharmacodynamic monitoring over 28- and 49-day periods. At the identified optimal dose range, GH increased 2- to 10-fold above baseline and remained elevated for at least 6 days, while IGF-1 rose 1.5- to 3-fold and remained elevated for 9-11 days per injection. With multiple doses, IGF-1 remained above baseline for the full 28-day observation period. No significant changes in prolactin, cortisol, or ACTH were detected, confirming selective activation of the GH/IGF-1 axis. (Evidence: Human Phase I - Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism)

Pulsatility Physiology {#research-pulsatility}

Ionescu and Frohman (2006) specifically investigated whether continuous GHRH receptor stimulation from CJC-1295 DAC would disrupt the normal pulsatile pattern of GH secretion. Using frequent blood sampling and GH pulse analysis, they confirmed that pulsatile GH secretion persists during continuous CJC-1295 DAC stimulation. The preserved pulsatile pattern implies continued somatostatin regulatory function - a meaningful indicator of maintained hypothalamic-pituitary feedback integrity. This differentiates the pharmacodynamic profile of CJC-1295 DAC from continuous exogenous GH infusion. The finding also adds important context to the theoretical GHRH receptor downregulation concern: while prolonged stimulation carries some risk, the pituitary's regulatory systems appear to remain at least partially functional. (Evidence: Human - Ionescu & Frohman, 2006, Journal of Clinical Endocrinology & Metabolism)

Preclinical Models of GH Deficiency {#research-gh-deficiency}

Preclinical research in GHRH knockout mice studied chronic CJC-1295 DAC administration in animals that do not produce GH normally. Regular administration normalized pituitary gland structure in these deficient animals, increased GH mRNA expression and total pituitary RNA, and produced apparent increases in somatotroph cell populations. These findings were frequency-dependent, with daily administration producing stronger effects than intermittent dosing. Cross-species pharmacodynamic consistency has been validated in rats, dogs, and pigs, strengthening the translational relevance of the human trial findings. (Evidence: Animal - preclinical only; cannot be directly extrapolated to human physiology)

Safety & Tolerability Research

The safety profile of CJC-1295 DAC in humans is defined entirely by the Phase I data from Teichman et al. (2006). Mild to moderate adverse events were reported in approximately 94% of active-treated subjects, compared to approximately 29% in the placebo group. The most frequent events were injection site reactions (approximately 70%), headache (63%), diarrhea (43%), and vasodilatory effects including flushing and transient blood pressure drops (approximately 30%). All adverse events resolved spontaneously without medical intervention. No serious adverse events were reported at the optimal dose range, and no clinically significant changes in blood glucose, liver function tests, or ECG readings were detected. No anti-drug antibodies formed across the trial population. Higher dose levels were associated with more frequent and more severe adverse events, reinforcing the rationale for staying within the identified optimal range.

Research Limitations

The published human evidence base for CJC-1295 DAC is narrow in specific ways worth naming directly. All human data derives from two Phase I trials in healthy adults - there are no Phase II efficacy trials, no data in populations with GH deficiency, no data in older adults experiencing age-related GH decline, and no data in any disease population. The maximum observation period in human trials is 49 days, meaning long-term safety beyond approximately seven weeks is unknown from published sources. Specific excretion pathways remain incompletely characterized. No head-to-head comparison data against other GHRH analogs or exogenous GH has been published. Body composition, recovery, and longevity applications - which represent the majority of real-world use - have no dedicated clinical trial data for this specific compound.

Is CJC-1295 DAC Legal? Regulatory & Sports Status

FDA status: CJC-1295 DAC is not approved by the FDA for any therapeutic indication. It is classified as a research compound in the United States and is not approved for human use, veterinary use, or clinical administration outside of formally registered investigational studies.

Research Use Only (RUO): In most jurisdictions, CJC-1295 DAC is classified as a research chemical. This classification means it is legally available for laboratory and scientific research purposes but is not authorized for human administration. The regulatory framework varies by country - some jurisdictions treat it as an unscheduled compound, others may require a prescription or have specific import restrictions.

WADA / USADA status: CJC-1295 DAC is not named as a specific substance on the current WADA Prohibited List. However, growth hormone-releasing peptides and related secretagogues fall under the broader category of "other growth hormone-releasing factors" prohibited under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) of the WADA Prohibited List. Any compound that acts on the GH/IGF-1 axis to elevate GH or IGF-1 is prohibited in sport regardless of whether it is named individually. Competitive athletes are responsible for understanding this categorical prohibition.

Country-specific notes: In Australia, CJC-1295 DAC falls under the scheduling framework of the Therapeutic Goods Administration (TGA) and is not approved for human use. In the UK, it would be regulated under the Medicines Act. In Canada, it falls under the Food and Drugs Act as an unapproved therapeutic product. Users in all jurisdictions are responsible for understanding and complying with local regulations, which can differ meaningfully.

Detection: Specific detection methods for CJC-1295 DAC in doping control have not been widely published. Given the compound's mechanism - stimulating endogenous GH secretion rather than introducing exogenous GH - direct detection is more technically challenging than for exogenous GH itself. However, indirect biomarker approaches including elevated GH and IGF-1 profiles are part of the biological passport framework used in competitive sports testing.

CJC-1295 DAC vs. Alternatives

Commonly Paired With - Synergistic Stacks

• CJC-1295 DAC + Ipamorelin: The most frequently documented stack in community and practitioner protocols. Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that stimulates GH release through a different receptor - the ghrelin receptor (GHSR) - rather than the GHRH receptor. Pairing a GHRH analog with a GHRP is mechanistically rational: the two pathways are complementary and their combination produces a synergistic GH pulse that exceeds what either compound produces alone. Ipamorelin is favored as the GHRP partner because of its high GH selectivity - it does not significantly raise cortisol or prolactin, preserving the hormonal selectivity that CJC-1295 DAC also maintains.

• CJC-1295 DAC + BPC-157: A pairing that appears in recovery-focused protocols, where CJC-1295 DAC contributes sustained IGF-1 elevation and BPC-157 contributes its documented tissue repair and angiogenic effects. The rationale is additive rather than synergistic - two different mechanisms working in parallel on repair and recovery goals. Documented in community and practitioner protocol data; no published clinical trial examines the combination directly.

• CJC-1295 DAC + Tesamorelin: Less common but documented in longevity and body composition protocols. Tesamorelin is an FDA-approved GHRH analog for HIV-associated lipodystrophy. Where both are included, the rationale typically centers on complementary GH secretagogue support, though combining two GHRH agonists requires careful consideration of cumulative GH elevation and the associated side effect profile.

Alternatives - When Another Peptide May Be Considered

CJC-1295 Without DAC (Modified GRF 1-29)

When someone wants GHRH receptor stimulation with a shorter, more controlled window - particularly for daily pulsatile protocols or for pairing with GHRPs in a timed approach - CJC-1295 without DAC is the closest alternative. Its half-life is approximately 30 minutes to 2 hours, making it active briefly around each injection rather than for nearly a week. This makes it suitable for people who want more control over dosing timing, are using GHRPs in a timed combination approach, or have concerns about the theoretical GHRH receptor downregulation risk associated with prolonged continuous stimulation.

Sermorelin

Sermorelin is a first-generation GHRH analog - the shortest active fragment of GHRH at 29 amino acids - and was the earliest compounded GHRH analog used in clinical and functional medicine contexts. Its half-life is shorter than CJC-1295 without DAC, making it even more transient. Sermorelin is sometimes preferred by practitioners working within compounding pharmacy frameworks given its longer history of clinical use and established safety documentation. It lacks the structural modifications that give CJC-1295 DAC its proteolytic resistance and albumin-binding capability.

Tesamorelin

Tesamorelin is the only GHRH analog with FDA approval, specifically for HIV-associated lipodystrophy. It has a robust published evidence base and is available through licensed compounding channels in some jurisdictions. It is a viable alternative when practitioners want a GHRH analog with more extensive regulatory documentation behind it, or when the goal aligns with its studied indication. It requires daily injection rather than weekly dosing given its shorter half-life.

Comparison table:

Build Your Protocol - MPP CTA

FAQs

What is CJC-1295 DAC?

CJC-1295 DAC is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH) - the natural signal the body uses to tell the pituitary gland to release growth hormone. The DAC (Drug Affinity Complex) component is a chemical modification that enables the peptide to bind covalently to albumin in the bloodstream, extending its active half-life from roughly 7 minutes to 5.8-8.1 days. It was developed by ConjuChem Biotechnologies and has been evaluated in two randomized, placebo-controlled Phase I human clinical trials published in 2006.

What does CJC-1295 DAC do?

CJC-1295 DAC stimulates the pituitary gland to release growth hormone in a sustained, pulsatile pattern from a single weekly injection. This GH elevation drives the liver to produce IGF-1, which remains elevated for 9-11 days per injection - and up to 28 days with repeated dosing. The downstream effects of elevated GH and IGF-1 include protein synthesis signaling, fat metabolism modulation, and cellular growth and repair; the compound does not meaningfully raise cortisol, prolactin, or ACTH at the doses studied in humans.

How long does CJC-1295 DAC take to work?

GH elevation begins within hours of a subcutaneous injection and is measurable on the day of dosing. Most users do not notice subjective effects this quickly - early-reported outcomes like improved sleep depth may begin appearing within the first 1-2 weeks, while body composition changes typically require 4-8 weeks of consistent protocol use to become noticeable. Individual variation is significant, and outcomes depend on dose, health status, diet, and training context.

What is the typical dose of CJC-1295 DAC?

Phase I human clinical trials identified an optimal tolerability window for subcutaneous injection, with the lower end of that range associated with the best tolerability profile and the upper end producing stronger GH and IGF-1 responses. Given the 5.8-8.1 day half-life, once-weekly injection is the minimum rational dosing interval. Individual protocols vary considerably based on health history, goals, and other compounds being used - the MyPeptidePal app builds personalized protocols based on your specific situation.

Is CJC-1295 DAC legal?

CJC-1295 DAC is not approved for human use by the FDA or equivalent agencies in most jurisdictions and is classified as a research compound. It is not specifically named on the WADA Prohibited List, but it falls under the categorical prohibition on growth hormone-releasing factors in Section S2 - meaning its use is banned in competitive sport regardless of the absence of a specific listing. Users are responsible for understanding applicable laws in their own country.

Can CJC-1295 DAC be taken orally?

No. CJC-1295 DAC is a 30-amino-acid peptide with a molecular weight of approximately 3,648 g/mol. Like all peptides of this size and complexity, it would be broken down by gastric acid and digestive enzymes in the gastrointestinal tract before reaching systemic circulation. Subcutaneous injection is required to deliver the compound intact into the bloodstream where it can form the albumin bond central to its mechanism of action.

What is the difference between CJC-1295 DAC and CJC-1295 without DAC?

The DAC modification is what separates these two compounds pharmacologically. CJC-1295 DAC binds covalently to albumin and has a half-life of 5.8-8.1 days, enabling once-weekly dosing. CJC-1295 without DAC (also called Modified GRF 1-29) lacks this albumin-binding mechanism and has a half-life of approximately 30 minutes to 2 hours, requiring daily or multiple-times-daily injection. The longer active window of the DAC version means more continuous GHRH receptor stimulation - which some see as convenient and others view as a theoretical concern for receptor downregulation.

Does CJC-1295 DAC need to be refrigerated?

Lyophilized (dry powder) CJC-1295 DAC should be stored at -20 degrees C for long-term storage and is stable for approximately 24 months under these conditions. Once reconstituted into solution, it requires refrigeration at 2-8 degrees C and should be used within 14-21 days. The reconstituted solution should be protected from light and should not be frozen after reconstitution.

Why does CJC-1295 DAC cause headaches?

Headache was the most common systemic adverse event in the Phase I trials, reported in approximately 63% of active participants. The most likely mechanism is the vasodilatory effect associated with GH and IGF-1 elevation - changes in vascular tone and transient blood pressure shifts can trigger headaches, particularly in the hours following injection. Flushing and sensation of warmth - also reported in approximately 30% of participants - are consistent with this vasodilatory picture. Headaches in the trial data resolved spontaneously without medical intervention.

Is CJC-1295 DAC the same as CJC-1295 with Ipamorelin?

No. CJC-1295 DAC and ipamorelin are separate compounds that are frequently used together in a stack. CJC-1295 DAC acts on the GHRH receptor to stimulate sustained GH secretion. Ipamorelin acts on the ghrelin receptor (GHSR) through a completely different mechanism to trigger a shorter, more acute GH pulse. When combined, they work through complementary pathways to produce a synergistic GH response. They are sometimes discussed together because the pairing is common, but they are chemically distinct compounds with different mechanisms, dosing frequencies, and pharmacological profiles.

Does CJC-1295 DAC require a cycle break?

No formal data from controlled trials exists on optimal cycling versus continuous use protocols for CJC-1295 DAC. The theoretical concern driving cycling practices is GHRH receptor downregulation with prolonged continuous stimulation - a more relevant concern with CJC-1295 DAC's extended half-life than with shorter-acting GHRH analogs. Many practitioners favor cycling approaches with periodic breaks for this reason, though the specific intervals that best preserve receptor sensitivity in humans have not been established in published research.

Final Thoughts

CJC-1295 DAC occupies a genuinely interesting position in the landscape of growth hormone-stimulating compounds. It is one of the few peptides in this category with real human clinical trial data behind it - two randomized, placebo-controlled Phase I studies that confirmed meaningful, sustained GH and IGF-1 elevation from a single weekly injection. The albumin-binding DAC technology represents a legitimate pharmacological innovation, not a marketing claim: extending a compound's half-life by more than 1,000-fold through covalent albumin binding is a real mechanism with real published pharmacokinetic evidence. The fact that pulsatile GH secretion is maintained despite continuous GHRH receptor stimulation adds a layer of pharmacodynamic nuance that distinguishes it from cruder approaches to GH elevation.

The evidence base has meaningful limitations that are worth being clear about. All human data comes from Phase I trials in healthy adults, covering a maximum of 49 days. There are no published efficacy trials, no data in GH-deficient populations, and no long-term safety data beyond seven weeks from the published literature. The body composition, recovery, and longevity applications that represent the majority of real-world use are mechanistically grounded but lack dedicated clinical evidence for this specific compound. The regulatory picture is equally straightforward: CJC-1295 DAC is not approved for human use in any jurisdiction and falls under the categorical prohibition on GH-releasing factors in competitive sport. Quality sourcing and protocol design matter - the compound's mechanism depends on precise structural chemistry, which means synthesis quality is not a secondary consideration.

If you are looking to understand what CJC-1295 DAC could mean for your specific situation - your health profile, your goals, the right dosing range, how it fits with anything else you are doing - that is exactly what the MyPeptidePal protocol builder is designed to help with. This guide covers the published evidence and the broad picture. The personalized layer lives in the app.

References

1. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.

2. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.